Cetera Trust Company, N.A Halozyme Therapeutics, Inc. Transaction History
Cetera Trust Company, N.A
- $159 Billion
- Q2 2024
A detailed history of Cetera Trust Company, N.A transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cetera Trust Company, N.A holds 5,540 shares of HALO stock, worth $328,023. This represents 0.18% of its overall portfolio holdings.
Number of Shares
5,540
Previous 5,540
-0.0%
Holding current value
$328,023
Previous $225 Million
28.71%
% of portfolio
0.18%
Previous 0.14%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
489Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$763 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$344 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$239 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$220 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.25B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...